Table 1.
Baseline characteristics of participants in the intention-to-treat cohort
| Aerosolised Ad5-nCoV group (n=117) | Intramuscular Ad5-nCoV group (n=120) | CoronaVac group (n=119) | ||
|---|---|---|---|---|
| Sex | ||||
| Female | 62 (53%) | 72 (60%) | 67 (56%) | |
| Male | 55 (47%) | 48 (40%) | 52 (44%) | |
| Age, years | ||||
| 60–70 | 20 (17%) | 16 (13%) | 16 (13%) | |
| 18–59 | 97 (83%) | 104 (87%) | 103 (87%) | |
| Mean* | 47·2 (11·3) | 46·4 (11·2) | 43·5 (12·2) | |
| Height, cm | 164·3 (8·3) | 163·8 (7·8) | 163·8 (7·1) | |
| Weight, kg | 70·8 (13·3) | 68·5 (13·2) | 67·3 (12·3) | |
| Time since the last priming dose of inactivated vaccine, months | 6·6 (6·5–8·6) | 6·6 (6·4–8·6) | 6·6 (6·4–8·6) | |
| Pre-existing Ad5-neutralising antibodies† | ||||
| Geometric mean titre | 182·6 (127·8–260·7) | 139·5 (95·2–204·3) | 166·0 (115·2–239·3) | |
| Participants with titre ≤1:200 | 48 (41%) | 54/118 (46%) | 54/116 (47%) | |
| Participants with titre >1:200 | 69 (59%) | 64/118 (54%) | 62/116 (53%) | |
Data are n (%), mean (SD), median (IQR,) or geometric mean titre (95% CI). The analysis was based on the intention-to-treat cohort, with some participants reclassified into the correct groups according to the vaccines that they received.
*
Significant differences were noted among all groups, with p=0·034.
†
Two in the intramuscular Ad5-nCoV group and three in the CoronaVac group failed to collect blood and therefore did not do the Ad5 neutralising antibody assay.